Summary Irritable bowel syndrome (IBS) is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least 3 months. The disorder is classified into three main subtypes, according to the predominant bowel habits presented: constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), and mixed-presentation IBS (IBS-M). IBS is among the most common gastrointestinal disorders, with an estimated pooled international IBS prevalence rate of about 11.2%. The global Irritable Bowel Syndrome (IBS) market will reach xxx Million USD in 2019 with CAGR xx% 2019-2025. The main contents of the report including: Global market size and forecast Regional market size, production data and export & import Key manufacturers profile, products & services, sales data of business Global market size by Major Application Global market size by Major Type Key manufacturers are included based on company profile, sales data and product specifications etc.: Valeant Pharmaceuticals Allergan Takeda Sucampo Pharmaceuticals McNeil Consumer Healthcare Sebela Pharmaceuticals Astellas Pharmaceuticals IM HealthScience Major applications as follows: Women Men Major Type as follows: IBS-D Drug IBS-C Drug Others Regional market size, production data and export & import: Asia-Pacific North America Europe South America Middle East & Africa
Table of Contents 1 Global Market Overview 1.1 Scope of Statistics 1.1.1 Scope of Products 1.1.2 Scope of Manufacturers 1.1.3 Scope of Application 1.1.4 Scope of Type 1.1.5 Scope of Regions/Countries 1.2 Global Market Size 2 Regional Market 2.1 Regional Production 2.2 Regional Demand 2.3 Regional Trade 3 Key Manufacturers 3.1 Valeant